CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Sold by Capital International Inc. CA

Capital International Inc. CA trimmed its position in CRISPR Therapeutics AG (NASDAQ:CRSP) by 3.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 99,292 shares of the company’s stock after selling 3,284 shares during the quarter. Capital International Inc. CA’s holdings in CRISPR Therapeutics were worth $3,908,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Highline Wealth Partners LLC purchased a new position in CRISPR Therapeutics in the fourth quarter worth approximately $39,000. Western Pacific Wealth Management LP lifted its stake in shares of CRISPR Therapeutics by 100.0% in the 4th quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company’s stock valued at $39,000 after purchasing an additional 500 shares during the last quarter. Wilmington Savings Fund Society FSB purchased a new position in shares of CRISPR Therapeutics during the 3rd quarter worth $40,000. Spire Wealth Management increased its position in shares of CRISPR Therapeutics by 303.7% during the 4th quarter. Spire Wealth Management now owns 1,970 shares of the company’s stock worth $78,000 after purchasing an additional 1,482 shares during the last quarter. Finally, MCF Advisors LLC purchased a new stake in CRISPR Therapeutics in the 4th quarter valued at about $80,000. Institutional investors and hedge funds own 69.20% of the company’s stock.

Analyst Ratings Changes

Several research analysts have weighed in on CRSP shares. Citigroup lowered their target price on shares of CRISPR Therapeutics from $89.00 to $82.00 and set a “buy” rating for the company in a research note on Tuesday, February 18th. Bank of America dropped their target price on shares of CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. Barclays upped their price target on CRISPR Therapeutics from $55.00 to $56.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 12th. Stifel Nicolaus dropped their price objective on CRISPR Therapeutics from $53.00 to $49.00 and set a “hold” rating for the company in a research note on Thursday, February 13th. Finally, Evercore ISI upgraded CRISPR Therapeutics from an “in-line” rating to an “outperform” rating and boosted their price objective for the company from $60.00 to $99.00 in a report on Friday, February 14th. Two analysts have rated the stock with a sell rating, nine have given a hold rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $73.11.

Insider Transactions at CRISPR Therapeutics

In related news, CEO Samarth Kulkarni sold 18,360 shares of the business’s stock in a transaction on Wednesday, February 19th. The shares were sold at an average price of $55.20, for a total value of $1,013,472.00. Following the completion of the sale, the chief executive officer now directly owns 171,613 shares of the company’s stock, valued at $9,473,037.60. The trade was a 9.66 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Julianne Bruno sold 1,198 shares of the firm’s stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total value of $50,819.16. Following the transaction, the chief operating officer now directly owns 8,263 shares in the company, valued at approximately $350,516.46. The trade was a 12.66 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 32,381 shares of company stock valued at $1,608,243. Corporate insiders own 4.10% of the company’s stock.

CRISPR Therapeutics Stock Down 0.0 %

NASDAQ CRSP opened at $37.77 on Monday. CRISPR Therapeutics AG has a 52 week low of $30.04 and a 52 week high of $67.88. The firm has a 50 day moving average of $40.93 and a two-hundred day moving average of $43.73. The stock has a market capitalization of $3.24 billion, a PE ratio of -8.64 and a beta of 1.85.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its earnings results on Tuesday, February 11th. The company reported ($0.44) EPS for the quarter, beating the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. On average, equities research analysts expect that CRISPR Therapeutics AG will post -5.16 earnings per share for the current fiscal year.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.